Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2020 / N 4

Возможности преодоления проблем поздних стадий болезни Паркинсона с помощью постоянной инфузии интестинального геля, содержащего леводопу/карбидопу
И.В. Литвиненко, А.А. Тимофеева, С.Ю. Киртаев, М.М. Одинак, А.А. Скоромец, А.С. Агафьина, А.А. Сахаровская

References

1. Guidelines for diagnosis and treatment of Parkinson’s disease. Illarioshkin SN, Levin OS, editors. Moscow: Pareto Print; 2017. 336 p (In Russian).
2. Extrapyramidal disorders. Guidelines for diagnosis and treatment. Shtok VN, Ivanova-Smolenskaya IA, Levin OS, editors. Moscow: Medpress-inform; 2002. 608 p. (In Russian).
3. Odin P, Russmann A, Bremenhaven A, Aquilonius SM. Pump-driven continuous duodenal administration of levodopa. A new therapy for patients with advanced Parkinson’s disease. Psychopharmakotherapie 2005 Nov;12:223-7.
4. Seliverstov YuA, Illarioshkin SN. Prevalence and main methods of treatment of advance stages of Parkinson’s disease. SS Korsakov Journal of Neurology and Psychiatry 2013;113(11):100-6 (In Russian).
5. Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson disease. Journal of Neural Transmission (Vienna, Austria: 1996) 2005 Mar;112(3):359-91.
6. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson’s disease. Neurology 2009 May;72 (21 Suppl 4):S1-136.
7. Fahn S, Poewe W. Levodopa: 50 years of a revolutionary drug for Parkinson disease. Movement Disorders 2015 Jan;30(1):1-3.
8. Illarioshkin SN. Parkinsonism therapy: opportunities and prospects. Consilium Medicum. Supplement 2009;1:35-40 (In Russian).
9. Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clinical Interventions in Aging 2010 Sep;7:229-38.
10. Parkinsonian disorders in сlinical practice. Schapira AH, Hartman A, Agid Y, editors. Oxford, Oxon.: Wiley-Blackwell; 2009. 208 p.
11. Litvinenko IV, Odinak MM, Sologub OS, Mogilnaya VI, Shmeleva VM, Sakharovskaya AA. Hyperhomocysteinemia in Parkinson’s disease – a new variant of complications in therapy or a specific biochemical marker of disease? Annals of Clinical and Experimental Neurology 2008;2(2):13-7 (In Russian).
12. Fahn S. Parkinson’s disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs later L-DOPA. Archives of Neurology 1999 May;56(5):529-35.
13. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and progression of Parkinson’s disease. The New England Journal of Medicine 2004 Dec;351(24):2498-508.
14. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism & Related Disorders 2001 Oct;8(2):95-100.
15. Levin OS. Levodopa and levodopaphobia. Neurological Journal 2010;15(4):4-11 (In Russian).
16. Parkinson’s disease and movement disorders. Jankovic J, Tolosa E, editors. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002. 704 p.
17. Levin OS, Fedorova NV. Parkinson’s disease. Moscow: MEDpress-inform; 2014. 384 p. (In Russian).
18. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson’s disease non-L-dopa-responsive problems dominate at 15 years. Movement Disorders 2005 Feb;20(2):190-9.
19. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Annals of Neurology 2006 Mar;59(3):559-62.
20. Schrag A, Quinn N. Dyskinesia and motor fluctuations in Parkinson’s disease. A community-based study. Brain 2000 Nov;123(Pt 11):2297-305.
21. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology 2004 Jan;62(1 Suppl 1):S56-63.
22. Slawek J, Bogucki A. Levodopa intestinal infusion therapy in Parkinson’s disease. Neurologia i Neurochirurgia Polska 2010 Jul-Aug;44(4):396-403.
23. Stowe R, Ives N, Clarke CE, Handley K, Furmston A, Deane K, van Hilten JJ, Wheatley K, Gray R. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson’s disease. Movement Disorders 2011 Mar;26(4):587-98.
24. Olanow CW. Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less. Movement Disorders 2019 Jun;34(6):812-5.
25. Managing advanced Parkinson’s disease: the role of continuous dopaminergic stimulation. Aquilonius SM, Lees AJ, editors. London: Scope Medical; 2007.
26. Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernäs H, Nyström C, Aquilonius SM. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clinical Neuropharmacology 2003 May-Jun;26(3):156-63.
27. Antonini A, Odin P, Opiano L, Tomantschger V, Pacchetti C, Pickut B, Gasser UE, Calandrella D, Mancini F, Zibetti M, Minafra B, Bertaina I, De Deyn P, Cras C, Wolf E, Spielberger S, Poewe W. Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicentral outcome assessment in patient routine care. Journal of Neural Transmission 2013;120:1553-8.
28. Nyholm D. Duodopa treatment for advanced Parkinson's disease: a review of efficacy and safety. Parkinsonism & Related Disorders 2012 Sep;18(8):916-29.
29. Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson’s disease therapeutics. Movement Disorders 2011 May;26(6):1072-82.
30. Instructions for medical use of Duodopa® drug. Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b2dd4328-20b9-444b-ae5c-91690cf81256&t= Accessed 2020 Dec 10 (In Russian).
31. Eggert K, Schrader C, Stamelou M, Rüssmann A, Dengler R, Oertel W, Odin P. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clinical Neuropharmacology 2008 May-Jun;31(3):151-66.
32. Nyholm D, Askmark H, Parsons R, Neville A. Treatment of advanced Parkinson’s disease with levodopa/carbidopa intestinal gel is associated with improvement in Hoehn and Yahr stage. Parkinsonism & Related Disorders 2012 Jun;18(5):686-7.
33. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson’s disease. European Journal of Neurology 2012 Aug;19(8):1079-85.
34. Fernandez H, Standaert D, Hauser R, Lang AE, Fung VSC, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Movement Disorders 2015 Apr;30(4):500-9.
35. Skoromets AA, Odinak MM, Yakupov EZ, Litvinenko IV, Zalyalova ZA, Timofeyeva AA, Kirtayev SYu, Bogdanov RR, Agafina AS, Chatamra K, Robieson W, Benesh J, Latypova GR, Yershova MV, Illarioshkin SN. Levodopa-carbidopa intestinal gel in treatment of patients with advanced stages of Parkinson’s disease: results of 12-month open study. SS Korsakov Journal of Neurology and Psychiatry 2017;117(2):22-31 (In Russian).
36. Odin P, Chaudhuri KR, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, Antonini A, Rascol O, Poewe W; National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism & Related Disorders 2015 Oct;21(10):1133-44.
37. Antonini А, Stoessl А, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin PLO. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Current Medical Research and Opinion 2015;12:2063-73.
38. Lökk J. Lack of information and access to advanced treatment for Parkinson’s disease patients. Journal of Multidisciplinary Healthcare 2011;4:433-9.
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]